Fluorine-19 NMR studies of tumor-bearing rats treated with difluoromethylornithine.
Copenhagen rats with implanted metastatic prostate carcinomas have been treated with the drug alpha-difluoromethylornithine (DFMO), an inhibitor of the enzyme ornithine decarboxylase. In vivo and in vitro 19F NMR observations were then carried out on a variety of organs and tissues. The distribution of the drug strongly favored tumor over surrounding muscle. DFMO, which gives a spectrum similar to that of the pH indicator difluoromethylalanine, has potential for determination of in vivo pH. However, in contrast to the alanine analog, DFMO exhibits a considerably smaller shift dependence in response to pH changes.
D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy*; D000818:Animals; D000518:Eflornithine / Q000627:therapeutic use*; D005461:Fluorine; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D051381:Rats
D005461:Fluorine; D000518:Eflornithine